Tocilizumab and adalimumab were used in patients with JIA or in cases of systemic inflammation characterized by elevated serum interleukin-6 (IL-6) or tumor necrosis factor-alpha (TNF-α) levels, respectively. The gene discussed is IL6; the disease is juvenile idiopathic arthritis.